Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks versus benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed “remission” as the most appropriate descriptive term, and HbA1c <6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. The group also made suggestions for active observation of individuals experiencing a remission and discussed further questions and unmet needs regarding predictors and outcomes of remission.

[1]  F. Rubino,et al.  Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial , 2021, The Lancet.

[2]  W. Herman,et al.  Metformin Should Be Used to Treat Prediabetes in Selected Individuals , 2020, Diabetes Care.

[3]  M. Davidson Metformin Should Not Be Used to Treat Prediabetes , 2020, Diabetes Care.

[4]  K. Khunti,et al.  Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis , 2020, BMJ.

[5]  W. Ming,et al.  Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women , 2020, Journal of diabetes research.

[6]  Roy Taylor,et al.  Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) , 2019, British Journal of Diabetes.

[7]  Angela M Rodrigues,et al.  Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[8]  R. Beck,et al.  Continuous Glucose Monitoring Profiles in Healthy Non-Diabetic Participants: A Multicenter Prospective Study. , 2019, The Journal of clinical endocrinology and metabolism.

[9]  Benjamin S. Aribisala,et al.  Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.

[10]  Benjamin S. Aribisala,et al.  Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.

[11]  R. Beck,et al.  Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring , 2018, Diabetes Care.

[12]  Thomas P. Smith,et al.  EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets. , 2018, Clinical chemistry.

[13]  Eyal Dassau,et al.  International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.

[14]  R. Beck,et al.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading , 2017, Diabetes Care.

[15]  H. Gerstein,et al.  Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial , 2017, The Journal of clinical endocrinology and metabolism.

[16]  Deepak L. Bhatt,et al.  Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.

[17]  W. Herman,et al.  Reconciliation of Type 2 Diabetes Remission Rates in Studies of Roux-en-Y Gastric Bypass , 2016, Diabetes Care.

[18]  Roy Taylor,et al.  Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction , 2016, Diabetes Care.

[19]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[20]  B. Zinman,et al.  Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes , 2016, BMJ Open Diabetes Research and Care.

[21]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations , 2016, Diabetes Care.

[22]  A. MacCormick,et al.  Progression of diabetic retinopathy after bariatric surgery , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[23]  Deepak L. Bhatt,et al.  Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes , 2015, Diabetes Care.

[24]  B. Zinman,et al.  Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. , 2013, The lancet. Diabetes & endocrinology.

[25]  R. Wing,et al.  Association of an intensive lifestyle intervention with remission of type 2 diabetes. , 2012, JAMA.

[26]  A. Ceriello The emerging challenge in diabetes: the "metabolic memory". , 2012, Vascular pharmacology.

[27]  D. Yue,et al.  Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? , 2012, ISRN endocrinology.

[28]  Benjamin S. Aribisala,et al.  Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.

[29]  C. Fox,et al.  Low Hemoglobin A1c and Risk of All-Cause Mortality Among US Adults Without Diabetes , 2010, Circulation. Cardiovascular quality and outcomes.

[30]  R. Klein,et al.  Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes , 2010, Diabetes.

[31]  R. Heine,et al.  Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.

[32]  Sonia Caprio,et al.  How Do We Define Cure of Diabetes? , 2009, Diabetes Care.

[33]  E. Barnes Between remission and cure: patients, practitioners and the transformation of leukaemia in the late twentieth century , 2007, Chronic illness.

[34]  G. Treviño Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation , 2007, Diabetes Care.

[35]  Mathias M. Müller,et al.  Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement , 2007, Diabetes Care.

[36]  E. Ferrannini,et al.  Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. , 2007, Diabetes care.

[37]  M. Panteghini,et al.  The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) , 2006, Clinical chemistry and laboratory medicine.

[38]  R. Taylor,et al.  Long-term progression of retinopathy after initiation of insulin therapy in Type 2 diabetes: an observational study , 2004, Diabetologia.

[39]  R. Paroni,et al.  Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood , 2002, Clinical chemistry and laboratory medicine.

[40]  B. Davies,et al.  European Association for the Study of Diabetes , 1984 .

[41]  C. Fox,et al.  Low Hemoglobin A 1 c and Risk of All-Cause Mortality Among US Adults Without Diabetes April , 2010 .

[42]  Consensus Committee Consensus statement on the worldwide standardisation of the HbA1c measurement , 2007, Diabetologia.

[43]  S. Inzucchi,et al.  Metformin: new understandings, new uses. , 2003, Drugs.

[44]  G. Striker Glucose toxicity. , 2001, Kidney international.

[45]  Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. , 1998, Archives of ophthalmology.